As in the above study, Leiteritz et al. reported that fenofibrate, a PPARα agonist used as a hypolipidemic drug, alleviated the paralytic phenotype induced by Aβ toxicity via activating the NHR-49/PPARα pathway in a C. elegans AD model [39]. Here, PPARA is linked to Alzheimer disease.